Abstract
Three parameters allowing to distinguish B and T lymphocyte populations, i.e., the presence of surface-associated immunoglobulins (slg), the electrophoretic mobility (EPM) and the responsiveness <i>in vitro </i>to bacterial lipopolysaccharide (LPS) and to concanavalin A (Con A), were studied on mouse spleen cells at various time intervals following a single injection of cyclophosphamide (300mg/kg body weight). 1 day after the treatment, B cells (sIg-bearing, slow EPM) were almost totally destroyed and likewise, the response to LPS was abolished. Regeneration of the B cell compartment did not begin before day 16 and was complete only by day 30. Reconstitution of the LPS responsiveness was found to parallel the reappearance of B cells. T cells were also affected by the treatment, although to a much lesser extent than B cells. A first T cell subpopulation, with a mean EMP = 1.10 <i>μ</i>msec<sup>––</sup><sup>1</sup> V<sup>––1</sup> cm, was destroyed by cyclophosphamide, while a large part of the second T cell subpopulation, with a mean EPM = 1.25 <i>μ</i>m sec<sup>––1</sup> V<sup>––1</sup> cm remained in the spleen. This strongly suggests that the former subpopulation probably corresponds to short-lived cells and the latter to long-lived ones. Con A responsiveness was diminished but never suppressed and recovered relatively early. Starting by day 8, complete regeneration of the T cell compartment was achieved by day 30.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International archives of allergy and applied immunology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.